MA56324B1 - Inhibiteurs de l'arginase et leurs procédés d'utilisation - Google Patents
Inhibiteurs de l'arginase et leurs procédés d'utilisationInfo
- Publication number
- MA56324B1 MA56324B1 MA56324A MA56324A MA56324B1 MA 56324 B1 MA56324 B1 MA 56324B1 MA 56324 A MA56324 A MA 56324A MA 56324 A MA56324 A MA 56324A MA 56324 B1 MA56324 B1 MA 56324B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compounds
- formula
- arginase inhibitors
- arginase
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 2
- 108700024123 Arginases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (ib) ou (vc), ou leur sel pharmaceutiquement acceptable, des compositions pharmaceutiques comprenant des composés de formule (ib) ou (vc), et leurs procédés d'utilisation pour le traitement de cancer ou de maladie respiratoire inflammatoire et l'inhibition de l'arginase, où r1 est -h or -c(o)ch(r1a)nhr1b ; et r1a est choisi parmi -h, -alkyle en (c1-c4) et ch2or1c ; r1b est -h ; ou selon une autre variante r1a et r1b, conjointement avec l'atome auquel ils sont fixés, forment un cycle hétérocyclique à 5 chaînons ; et r1c est -h ou -ch3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802765P | 2019-02-08 | 2019-02-08 | |
| PCT/IB2020/050982 WO2020161675A1 (fr) | 2019-02-08 | 2020-02-07 | Inhibiteurs de l'arginase et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56324B1 true MA56324B1 (fr) | 2023-10-31 |
Family
ID=69770954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56324A MA56324B1 (fr) | 2019-02-08 | 2020-02-07 | Inhibiteurs de l'arginase et leurs procédés d'utilisation |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20220106335A1 (fr) |
| EP (1) | EP3921033B1 (fr) |
| JP (1) | JP7526734B2 (fr) |
| KR (1) | KR20210126044A (fr) |
| CN (1) | CN113395996B (fr) |
| AU (1) | AU2020218651B2 (fr) |
| BR (1) | BR112021015581A2 (fr) |
| CA (1) | CA3127755A1 (fr) |
| CL (1) | CL2021002056A1 (fr) |
| CO (1) | CO2021011039A2 (fr) |
| CR (1) | CR20210463A (fr) |
| DK (1) | DK3921033T3 (fr) |
| DO (1) | DOP2021000166A (fr) |
| EA (1) | EA202192114A1 (fr) |
| ES (1) | ES2960034T3 (fr) |
| FI (1) | FI3921033T3 (fr) |
| HR (1) | HRP20231092T1 (fr) |
| HU (1) | HUE062968T2 (fr) |
| IL (1) | IL285108B1 (fr) |
| LT (1) | LT3921033T (fr) |
| MA (1) | MA56324B1 (fr) |
| MX (1) | MX2021009499A (fr) |
| PE (1) | PE20220280A1 (fr) |
| PL (1) | PL3921033T3 (fr) |
| PT (1) | PT3921033T (fr) |
| RS (1) | RS64781B1 (fr) |
| SG (1) | SG11202108503PA (fr) |
| SI (1) | SI3921033T1 (fr) |
| WO (1) | WO2020161675A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| SE0300907D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Novel compounds |
| HUE046932T2 (hu) * | 2009-01-26 | 2020-04-28 | Univ Pennsylvania | Argináz inhibitorok és felhasználási eljárások |
| MY162535A (en) | 2010-04-22 | 2017-06-15 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| RS54750B1 (sr) * | 2010-10-26 | 2016-10-31 | Mars Inc | Borati kao inhibitori arginaze |
| US9266908B2 (en) * | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| MX2015007797A (es) * | 2012-12-17 | 2015-10-05 | Parion Sciences Inc | Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida. |
| PL410665A1 (pl) * | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2016210106A1 (fr) * | 2015-06-23 | 2016-12-29 | Calithera Biosciences, Inc. | Compositions et procédés d'inhibition de l'activité de l'arginase |
| WO2017175185A1 (fr) * | 2016-04-08 | 2017-10-12 | Novartis Ag | Dérivés d'acide hétéroaryl butanoïque utilisés en tant qu'inhibiteurs de la lta4h |
| AU2017382405B2 (en) | 2016-12-22 | 2021-12-16 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| CN108794517B (zh) * | 2017-04-27 | 2021-03-30 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
| MX2020008570A (es) * | 2018-02-17 | 2020-09-21 | Astrazeneca Ab | Inhibidores de arginasa y sus metodos de uso. |
| WO2019205979A1 (fr) * | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | Dérivé d'acide aminé non naturel, composition pharmaceutique le contenant, son procédé de préparation et son utilisation |
| KR102668252B1 (ko) * | 2018-08-22 | 2024-05-21 | 아스트라제네카 아베 | 아르기나제 저해제 및 이의 사용 방법 |
-
2020
- 2020-02-07 IL IL285108A patent/IL285108B1/en unknown
- 2020-02-07 BR BR112021015581-3A patent/BR112021015581A2/pt unknown
- 2020-02-07 LT LTEPPCT/IB2020/050982T patent/LT3921033T/lt unknown
- 2020-02-07 SI SI202030267T patent/SI3921033T1/sl unknown
- 2020-02-07 FI FIEP20709706.4T patent/FI3921033T3/fi active
- 2020-02-07 PL PL20709706.4T patent/PL3921033T3/pl unknown
- 2020-02-07 CN CN202080012567.4A patent/CN113395996B/zh active Active
- 2020-02-07 MX MX2021009499A patent/MX2021009499A/es unknown
- 2020-02-07 JP JP2021546232A patent/JP7526734B2/ja active Active
- 2020-02-07 WO PCT/IB2020/050982 patent/WO2020161675A1/fr active Application Filing
- 2020-02-07 MA MA56324A patent/MA56324B1/fr unknown
- 2020-02-07 HU HUE20709706A patent/HUE062968T2/hu unknown
- 2020-02-07 PT PT207097064T patent/PT3921033T/pt unknown
- 2020-02-07 SG SG11202108503PA patent/SG11202108503PA/en unknown
- 2020-02-07 AU AU2020218651A patent/AU2020218651B2/en active Active
- 2020-02-07 CA CA3127755A patent/CA3127755A1/fr active Pending
- 2020-02-07 US US17/429,011 patent/US20220106335A1/en active Pending
- 2020-02-07 DK DK20709706.4T patent/DK3921033T3/da active
- 2020-02-07 PE PE2021001295A patent/PE20220280A1/es unknown
- 2020-02-07 RS RS20230898A patent/RS64781B1/sr unknown
- 2020-02-07 KR KR1020217028170A patent/KR20210126044A/ko not_active Application Discontinuation
- 2020-02-07 EP EP20709706.4A patent/EP3921033B1/fr active Active
- 2020-02-07 CR CR20210463A patent/CR20210463A/es unknown
- 2020-02-07 ES ES20709706T patent/ES2960034T3/es active Active
- 2020-02-07 HR HRP20231092TT patent/HRP20231092T1/hr unknown
- 2020-02-07 EA EA202192114A patent/EA202192114A1/ru unknown
-
2021
- 2021-08-04 CL CL2021002056A patent/CL2021002056A1/es unknown
- 2021-08-06 DO DO2021000166A patent/DOP2021000166A/es unknown
- 2021-08-23 CO CONC2021/0011039A patent/CO2021011039A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20231092T1 (hr) | 2023-12-22 |
| MX2021009499A (es) | 2021-09-08 |
| CR20210463A (es) | 2021-10-15 |
| CL2021002056A1 (es) | 2022-03-04 |
| KR20210126044A (ko) | 2021-10-19 |
| AU2020218651B2 (en) | 2023-01-12 |
| HUE062968T2 (hu) | 2023-12-28 |
| SG11202108503PA (en) | 2021-09-29 |
| EP3921033A1 (fr) | 2021-12-15 |
| EP3921033B1 (fr) | 2023-07-26 |
| CO2021011039A2 (es) | 2021-09-09 |
| BR112021015581A2 (pt) | 2021-10-05 |
| EA202192114A1 (ru) | 2021-12-01 |
| PT3921033T (pt) | 2023-10-11 |
| DOP2021000166A (es) | 2021-09-30 |
| CA3127755A1 (fr) | 2020-08-13 |
| DK3921033T3 (da) | 2023-10-16 |
| JP2022521474A (ja) | 2022-04-08 |
| US20220106335A1 (en) | 2022-04-07 |
| IL285108B1 (en) | 2024-06-01 |
| FI3921033T3 (fi) | 2023-09-15 |
| CN113395996B (zh) | 2024-05-28 |
| SI3921033T1 (sl) | 2023-11-30 |
| IL285108A (en) | 2021-09-30 |
| JP7526734B2 (ja) | 2024-08-01 |
| CN113395996A (zh) | 2021-09-14 |
| ES2960034T3 (es) | 2024-02-29 |
| WO2020161675A1 (fr) | 2020-08-13 |
| PL3921033T3 (pl) | 2024-01-15 |
| RS64781B1 (sr) | 2023-11-30 |
| LT3921033T (lt) | 2023-09-25 |
| PE20220280A1 (es) | 2022-02-25 |
| AU2020218651A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008570A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| RU2581367C2 (ru) | Соединения для лечения рака | |
| MA49952B1 (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
| WO2019023145A1 (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp | |
| WO2017040993A4 (fr) | Petites molécules inhibitrices de dyrk1a et leurs utilisations | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA34450B1 (fr) | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique | |
| EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| MA47469B1 (fr) | Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer | |
| CA2626402A1 (fr) | Inhibiteurs du canal potassique | |
| MA45888A1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| WO2012027481A9 (fr) | Composés utilisés dans le traitement du cancer | |
| JPWO2016017826A1 (ja) | キサンチンオキシダーゼ阻害薬 | |
| MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| MA56324B1 (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| MA34746B1 (fr) | Dérivés de diphénylamine : utilisations, procédés de synthèse et compositions pharmaceutiques | |
| EA202191349A1 (ru) | 1,3,4-оксадиазолон и фармацевтический препарат | |
| JPWO2022029138A5 (fr) | ||
| MX2022007044A (es) | Compuesto y composicion como inhibidor de cinasa del receptor de los factores de crecimiento derivados de las plaquetas (pdgf). | |
| MA35878B1 (fr) | Utilisation thérapeutique de dérivés d'imidazopyridine |